Navigation Links
SeQual Technologies, American Lung Association of California and Seton Medical Center Partner to Support Survivor & Cyclist in 500-Mile California Ride
Date:7/24/2008

symptoms which, over time, can lead to muscle weakness and worsening of breathlessness.

"Mark Junge is an inspiration to those who live with lung disease. Lung health is important to everyone and having a lung disease does not mean the end of an active and happy lifestyle," said Chris Garvey, FNP, MSN, MPA, FAACVPR, Manager, Pulmonary and Cardiac Rehabilitation, for Seton Medical Center and longtime volunteer with the American Lung Association of California. "Seton Medical Center and the American Lung Association of California are honored to be partnering with SeQual and Mark as he begins his challenging journey from our hospital on July 24, bringing hope to those who suffer from chronic lung disease. As Mark's actions prove, regular physical activity, education and support can improve physical function, shortness of breath, fatigue and lessen the risk of hospitalization in those suffering from chronic lung disease."

"I'm not letting lung disease slow me down," said Junge. "By conquering the California Coast by bike with the help of my Eclipse portable oxygen device from SeQual, we are showing everyone that being on oxygen doesn't make you home-bound. Everything starts with an idea. The rest is logistics."

The Eclipse is the only oxygen concentrator on the market that provides continuous flow in a 24- hour/7-days-per-week portable device. Weighing only 17 pounds and at roughly the size of a child's backpack, the Eclipse pulls oxygen from the air and delivers it in nearly-pure form to those with breathing or lung difficulties. With the portability of the Eclipse, Mark can still live an active, independent life.

"For more than a decade, SeQual has been committed to innovations to improve the delivery and safety of medical oxygen," said Ron Richard, CEO of SeQual Technologies. "We are greatly privileged to support Mark on his impressive ride, and are hopeful his story will encourage others to seek treatment for their chronic lung disease to
'/>"/>

SOURCE SeQual Technologies Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4

Related medicine news :

1. San Diegos SeQual Technologies Loans 35 Portable Oxygen Units to Evacuees at Qualcomm Stadium
2. US Army Purchases SeQuals Cutting-Edge Oxygen Generation Technology for MRAP Deployment
3. ReBuilder Medical Technologies, Inc. Reports International Sales Expansion
4. ReBuilder Medical Technologies, Inc. Signs Agreement for Distribution in Maine
5. MedCom USAs Subsidiary Card Activation Technologies, Inc.s SB2 Registration Declared Effective by SEC
6. Neurobiological Technologies, Inc. Announces Receipt of Determination Letter from NASDAQ
7. ReBuilder Medical Technologies, Inc. Increases Staffing by 30% in Three Weeks Due to Increase in Demand for All ReBuilder Medical Products
8. ReBuilder Medical Technologies, Inc. Reports Monthly Sales in 2007 Nearly Doubling Monthly Sales in 2006, Including Record Daily Sales in September 2007
9. ReBuilder Medical Technologies, Inc. Contracts with ETS to Manufacture the Newest Version of its ReBuilder Neuropathy Treatment Device; Expects Sales to Increase 30%
10. ReBuilder Medical Technologies, Inc. Announces Agreement with Internet Marketer Helio Health; Anticipates 12% Additional Profit
11. ReBuilder Medical Technologies, Inc. Announces UK Demand for Safe Molluscum Contagiosum Treatment Leads to Distribution Agreement with UFFE Medical, LTD. Expected 10% Sales Increase.
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/29/2008)...esults of a 10-year study published in the August ...found that magnesium sulfate administered to women...he risk of cerebral palsy by 50 percent. The Benef...) trial was conducted in 18 centers in the U.S., i...renatal intervention ever found to reduce the inst...
(Date:8/29/2008)... http://www.aronowitzmd.com [Los An...espected experience in plastic surgery procedures ...consideration may be necessary for these patients,...e an established specialty of procedures for after...es, CA (PRWEB) August 29, 2008 -- Bariatric surger...
(Date:8/28/2008)...ues increase 138% versus Q2 2007 - Nine new Cen...RNewswire-FirstCall/ - CRH Medical Corporation,(CR... three and six months,ended June 30, 2008 (all fig...ths ended June 30, 2008 increased 138% to $1,653,8...7. Revenue for the six months ended June,30, 2008 ...
(Date:8/28/2008)...ion will be based in the Northeast region with mor...xt year, HARRISBURG, Pa., Aug. 28 /PRNewswire-USN...ity has hired a Patient Safety Liaison for the,Nor...eport to the,Pennsylvania Patient Safety Reporting...ylvania citizens., "Last year in focus groups wit...
Breaking Medicine News(10 mins):Health News:National study shows magensium sulfate reduces risk of cerebral palsy in premature births 2Health News:Dr. Joel Aronowitz, Specialist in Los Angeles Body Lift, Announces Plastic Surgery Options After Bariatric Surgery Weight Loss 2Health News:Dr. Joel Aronowitz, Specialist in Los Angeles Body Lift, Announces Plastic Surgery Options After Bariatric Surgery Weight Loss 3Health News:Dr. Joel Aronowitz, Specialist in Los Angeles Body Lift, Announces Plastic Surgery Options After Bariatric Surgery Weight Loss 4Health News:CRH Medical reports Q2 2008 results 2Health News:CRH Medical reports Q2 2008 results 3Health News:CRH Medical reports Q2 2008 results 4Health News:CRH Medical reports Q2 2008 results 5Health News:Pennsylvania Patient Safety Authority Hires Patient Safety Liaison to Help Healthcare Facilities Implement Guidance 2Health News:Pennsylvania Patient Safety Authority Hires Patient Safety Liaison to Help Healthcare Facilities Implement Guidance 3
...ngland register the lowest number of early deaths ...ls of obesity and the longest life expectancy. By...s the lowest life expectancy for men. Near neighbo...men. Those in both cities live, on average, near...
...ng the link between levels of urate in the blood a...the Harvard School of Public Health (HSPH) have fo...ted with a reduced risk of the disease. Urate is...ugh high levels can lead to gout, urate might also...
...er for three years. Circuit Judge Weber McCraw, wh...r the option of serving some of her sentence in a...nnessee preacher told the Jurors presiding over he... shot her husband. She had been suffering domestic...
...patients who have recently suffered a major heart ...rom their own bone marrow during routine coronary...her the stem cells will repair heart muscle cells ...ing late scar formation and hence impaired heart c...
Other Medicine News:Health News:Southern England Far Healthier Than the North 2Health News:Urate Reduces the Risk of Parkinsons Disease 2Health News:Domestic Abuse Led Wife Killing Her Preacher Husband 2Health News:A New Milestone in Stem Cell Research 2
(Date:8/27/2008)...tients in the VELCADE, melphalan and prednisone ar... well as a 30 percent complete response -, CAMBRI...e Takeda,Oncology Company today announced the publ...d, Phase III VISTA(1) trial in this week,s edition...ts showed a significant survival,benefit and a 30 ...
(Date:8/27/2008)...First Phase 3 data, from BLISS-52 trial, expected ...LISS-76, expected by fall 2009 -, ROCKVILLE, Md.,...iences, Inc. (Nasdaq: HGSI ) today announced it h...S-76, the second of two pivotal Phase 3,randomized... patients with,active systemic lupus erythematosus...
(Date:8/26/2008)...IANAPOLIS, Aug. 26 /- Semafore Pharma...national Congress on Targeted Therapies,in Cancer ...ovel,multi-targeted kinase inhibitors that demonst...l studies., A novel and proprietary molecular sca...ing allowing for the design of pan-PI3 kinase inhi...
(Date:8/26/2008)...LO PARK, Calif., Aug. 26 /-... the positive one-year follow-up data,from the CUS...e of the,peer-reviewed journal, EuroIntervention. ...tella, M.D., of University Medical Center Utrecht,...II Investigators from 13 clinical,sites across Eur...
Breaking Medicine Technology:New England Journal of Medicine Publishes Phase III Results of VELCADE(R) (Bortezomib) for Injection in Previously Untreated Multiple Myeloma Patients 2New England Journal of Medicine Publishes Phase III Results of VELCADE(R) (Bortezomib) for Injection in Previously Untreated Multiple Myeloma Patients 3New England Journal of Medicine Publishes Phase III Results of VELCADE(R) (Bortezomib) for Injection in Previously Untreated Multiple Myeloma Patients 4New England Journal of Medicine Publishes Phase III Results of VELCADE(R) (Bortezomib) for Injection in Previously Untreated Multiple Myeloma Patients 5New England Journal of Medicine Publishes Phase III Results of VELCADE(R) (Bortezomib) for Injection in Previously Untreated Multiple Myeloma Patients 6Human Genome Sciences Completes Enrollment in Second Phase 3 LymphoStat-B(R) Trial 2Human Genome Sciences Completes Enrollment in Second Phase 3 LymphoStat-B(R) Trial 3Human Genome Sciences Completes Enrollment in Second Phase 3 LymphoStat-B(R) Trial 4Human Genome Sciences Completes Enrollment in Second Phase 3 LymphoStat-B(R) Trial 5Human Genome Sciences Completes Enrollment in Second Phase 3 LymphoStat-B(R) Trial 6Semafore Broadens Pipeline With Multi-Targeted Kinase Inhibitors 2Semafore Broadens Pipeline With Multi-Targeted Kinase Inhibitors 3XTENT Announces CUSTOM II Data Selected for Publication in EuroIntervention 2XTENT Announces CUSTOM II Data Selected for Publication in EuroIntervention 3XTENT Announces CUSTOM II Data Selected for Publication in EuroIntervention 4Blood pressure drug telmisartan shows powerful activity against stroke 1570 1Blood pressure drug telmisartan shows powerful activity against stroke 1570 2Blood pressure drug telmisartan shows powerful activity against stroke 1570 3Ireland Cancer Center researchers advance stem cell gene therapy 1565 1Ireland Cancer Center researchers advance stem cell gene therapy 1565 2Ireland Cancer Center researchers advance stem cell gene therapy 1565 3Wind power explored off Californias coast 1563 1Wind power explored off Californias coast 1563 2Wind power explored off Californias coast 1563 3Wind power explored off Californias coast 1563 4Ceregene Presents Long term Follow up From Phase 1 Trial of CERE 120 in Parkinsons Disease 1050 1Ceregene Presents Long term Follow up From Phase 1 Trial of CERE 120 in Parkinsons Disease 1050 2Ceregene Presents Long term Follow up From Phase 1 Trial of CERE 120 in Parkinsons Disease 1050 3Ceregene Presents Long term Follow up From Phase 1 Trial of CERE 120 in Parkinsons Disease 1050 4
The PachPen uses state-of-the-art waveform analysis and a probe that samples at a 65MHz rate to obtain precise readings. The PachPen stores and averages nine measurements and calculates IOP correctio
...ailable as both regular and filter tips. Sterilize...re efficient sterilization and are delivered with ...e of irradiation. Sterilized Diamond Tips are read...k Diamond Tips are wrapped in medical device quali...
300 L, Bulk Recommended for 250 and 300 L pipettes.
Ambion's barrier tips prevent cross-contamination of samples by means of an aerosol filter. They are RNase- and DNase-free and are ideal for handling RNA, PCR applications, and for working with radio
Medicine Products: